Everything You Need to Know About AstraZeneca's Dividend and Recent News Before Aug 8, 2025
Generated by AI AgentAinvest Dividend Digest
Tuesday, Aug 5, 2025 7:08 am ET1min read
AZN--
Aime Summary
Aime SummaryAstraZeneca has announced its upcoming dividend, set at $0.515 per share. The ex-dividend date is Aug 8, 2025, with the dividend payment scheduled for Sept 8, 2025. This dividend is slightly lower than the average of the last ten dividends, which stands at $0.755 per share. The previous dividend, paid on Mar 24, 2025, was markedly higher at $1.050 per share. Both dividends are categorized as cash dividends. Investors should note the ex-dividend date is crucial, marking the deadline for purchasing shares to be eligible for the dividend payout.
Recently, AstraZeneca's second-quarter earnings report showcased impressive revenue performance, surpassing expectations. However, the earnings per share did not meet forecasts, indicating a mixed result for the company. Analysts noted that this discrepancy could influence investor sentiment and market dynamics.
As of late, AstraZenecaAZN-- has expanded its collaboration with SOPHiA GENETICSSOPH--. This partnership involves utilizing AI technologies to analyze diverse healthcare data, including genomics and imaging. Such advancements are expected to bolster AstraZeneca's capabilities in the healthcare sector, potentially impacting its operational efficiency and market standing.
Over the past week, AstraZeneca's turnover on Aug 4, 2025, was reported at $259.970 million, placing it 420th in the market rankings with a volume of 3.510 million shares. This recent financial activity underscores the company's active presence in the market and might reflect its current standing among competitors.
In conclusion, AstraZeneca continues to be a key player in the pharmaceutical industry, with recent developments and financial performances shaping its market trajectory. Investors should be aware that Aug 8, 2025, is the last day to purchase shares to qualify for the upcoming dividend, as any transactions made after this date will not grant entitlement to the dividend payout.
Recently, AstraZeneca's second-quarter earnings report showcased impressive revenue performance, surpassing expectations. However, the earnings per share did not meet forecasts, indicating a mixed result for the company. Analysts noted that this discrepancy could influence investor sentiment and market dynamics.
As of late, AstraZenecaAZN-- has expanded its collaboration with SOPHiA GENETICSSOPH--. This partnership involves utilizing AI technologies to analyze diverse healthcare data, including genomics and imaging. Such advancements are expected to bolster AstraZeneca's capabilities in the healthcare sector, potentially impacting its operational efficiency and market standing.
Over the past week, AstraZeneca's turnover on Aug 4, 2025, was reported at $259.970 million, placing it 420th in the market rankings with a volume of 3.510 million shares. This recent financial activity underscores the company's active presence in the market and might reflect its current standing among competitors.
In conclusion, AstraZeneca continues to be a key player in the pharmaceutical industry, with recent developments and financial performances shaping its market trajectory. Investors should be aware that Aug 8, 2025, is the last day to purchase shares to qualify for the upcoming dividend, as any transactions made after this date will not grant entitlement to the dividend payout.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet